NCT06420115 Can Needle Size Improve Cancer Detection Rate of Transperineal MRI Target Prostate Biopsy Without Affecting Side Effects?
| NCT ID | NCT06420115 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Padova |
| Condition | Prostate Cancer Diagnosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 580 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 580 participants in total. It began in 2024-06-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Differences in terms of diagnostic capability and side effects related to the needle caliber used for prostate biopsy sampling in patients with suspected prostate cancer
Eligibility Criteria
Inclusion Criteria: * Clinical suspicion of prostate cancer (presence of elevated prostatic specific antigen and/or suspicious digital rectal examination); * Presence of at least one suspicious prostate lesion on MRI (Prostate Imaging-Reporting and Data System ≥ 3) according to the Prostate Imaging-Reporting and Data System v2.1 performed before Magnetic Resonance Imaging/transrectal ultrasound fusion biopsy. Exclusion Criteria: * Patients under active surveillance or with a previous diagnosis of prostate neoplasia prior to biopsy. * Previous radiotherapy to the prostate for neoplasia.
Contact & Investigator
Fabio Zattoni, MD, PhD
PRINCIPAL INVESTIGATOR
Department of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padua, Padova,
Frequently Asked Questions
Who can join the NCT06420115 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancer Diagnosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06420115 currently recruiting?
Yes, NCT06420115 is actively recruiting participants. Contact the research team at fabio.zattoni@unipd.it for enrollment information.
Where is the NCT06420115 trial being conducted?
This trial is being conducted at Padua, Italy.
Who is sponsoring the NCT06420115 clinical trial?
NCT06420115 is sponsored by University Hospital Padova. The principal investigator is Fabio Zattoni, MD, PhD at Department of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padua, Padova,. The trial plans to enroll 580 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.